These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 24472707)

  • 21. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
    Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
    BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
    Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
    Generali D; Buffa FM; Berruti A; Brizzi MP; Campo L; Bonardi S; Bersiga A; Allevi G; Milani M; Aguggini S; Papotti M; Dogliotti L; Bottini A; Harris AL; Fox SB
    J Clin Oncol; 2009 Jan; 27(2):227-34. PubMed ID: 19064988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway.
    Yang Y; Cong H; Han C; Yue L; Dong H; Liu J
    Oncol Rep; 2015 Oct; 34(4):1755-60. PubMed ID: 26239613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
    He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
    Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
    Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
    Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
    Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
    Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
    Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    Masri S; Phung S; Wang X; Chen S
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
    Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
    PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.